The Asia Pacific Cluster Headache Market should witness market growth of 4.8% CAGR during the forecast period (2022-2028).
Periodic headache-causing triggers include the brain's blood vessels shifting in response to headaches. People become more susceptible to nicotine and alcohol due to these changes. Even a small amount of alcohol consumption might cause headaches. Smoking can also exacerbate headaches or even cause them. Just on the side of the headache the nose starts to flow or get stuffy. Eye issues include eye discomfort, watery eyes, and drooping eyelids. The patient’s pupil, which is the dark spot in the middle of the eye, could also appear smaller. On the headache side, patients can start sweating, and their face might get flushed.
Even though cluster headaches are incurable, some treatments might lessen their discomfort. Abortive care to halt attacks: A headache frequently ends before the patientcan consult a doctor. Yet, several efficient techniques exist to stop a cluster headache if the patientacts quickly. One could receive a nasal spray or an injection of medicine from a medical professional. Sumatriptan, dihydroergotamine, and zolmitriptan are a few of them.They could also receive oxygen from the supplier via a mask.
The pharmaceutical sector in India is worth $50 billion. 3.5% of all medications and medicines shipped internationally to more than 200 nations come from this nation. The Department of Pharmaceuticals has introduced three supporting programs to encourage international and domestic players to increase investment and production in these product categories to ensure greater resilience to external shocks, enforce greater drug security, and increase domestic production capacity for critical bulk drugs high-value products alike. The Schemes are intended to increase the Indian pharmaceutical industry's resilience to external shocks and significantly advance the achievement of a higher goal of sustainable access to inexpensive healthcare domestically and abroad. This supports the growth of the regional market.
The China market dominated the Asia Pacific Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $34.5 Million by 2028. The Japan market is estimated to grow a CAGR of 4.2% during (2022-2028). Additionally, The India market would display a CAGR of 5.4% during (2022-2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Periodic headache-causing triggers include the brain's blood vessels shifting in response to headaches. People become more susceptible to nicotine and alcohol due to these changes. Even a small amount of alcohol consumption might cause headaches. Smoking can also exacerbate headaches or even cause them. Just on the side of the headache the nose starts to flow or get stuffy. Eye issues include eye discomfort, watery eyes, and drooping eyelids. The patient’s pupil, which is the dark spot in the middle of the eye, could also appear smaller. On the headache side, patients can start sweating, and their face might get flushed.
Even though cluster headaches are incurable, some treatments might lessen their discomfort. Abortive care to halt attacks: A headache frequently ends before the patientcan consult a doctor. Yet, several efficient techniques exist to stop a cluster headache if the patientacts quickly. One could receive a nasal spray or an injection of medicine from a medical professional. Sumatriptan, dihydroergotamine, and zolmitriptan are a few of them.They could also receive oxygen from the supplier via a mask.
The pharmaceutical sector in India is worth $50 billion. 3.5% of all medications and medicines shipped internationally to more than 200 nations come from this nation. The Department of Pharmaceuticals has introduced three supporting programs to encourage international and domestic players to increase investment and production in these product categories to ensure greater resilience to external shocks, enforce greater drug security, and increase domestic production capacity for critical bulk drugs high-value products alike. The Schemes are intended to increase the Indian pharmaceutical industry's resilience to external shocks and significantly advance the achievement of a higher goal of sustainable access to inexpensive healthcare domestically and abroad. This supports the growth of the regional market.
The China market dominated the Asia Pacific Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $34.5 Million by 2028. The Japan market is estimated to grow a CAGR of 4.2% during (2022-2028). Additionally, The India market would display a CAGR of 5.4% during (2022-2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Scope of the Study
By Distribution channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Others
By Type
- Episodic
- Chronic
By Drug Class
- Triptans
- Calcium Channel Blockers
- Ergot Derivatives
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Dr.Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Cluster Headache Market, by Distribution channel
1.4.2 Asia Pacific Cluster Headache Market, by Type
1.4.3 Asia Pacific Cluster Headache Market, by Drug Class
1.4.4 Asia Pacific Cluster Headache Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Cluster Headache Market by Distribution channel
3.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
3.2 Asia Pacific Hospital Pharmacies Market by Country
3.3 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Cluster Headache Market by Type
4.1 Asia Pacific Episodic Market by Country
4.2 Asia Pacific Chronic Market by Country
Chapter 5. Asia Pacific Cluster Headache Market by Drug Class
5.1 Asia Pacific Triptans Market by Country
5.2 Asia Pacific Calcium Channel Blockers Market by Country
5.3 Asia Pacific Ergot Derivatives Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Cluster Headache Market by Country
6.1 China Cluster Headache Market
6.1.1 China Cluster Headache Market by Distribution channel
6.1.2 China Cluster Headache Market by Type
6.1.3 China Cluster Headache Market by Drug Class
6.2 Japan Cluster Headache Market
6.2.1 Japan Cluster Headache Market by Distribution channel
6.2.2 Japan Cluster Headache Market by Type
6.2.3 Japan Cluster Headache Market by Drug Class
6.3 India Cluster Headache Market
6.3.1 India Cluster Headache Market by Distribution channel
6.3.2 India Cluster Headache Market by Type
6.3.3 India Cluster Headache Market by Drug Class
6.4 South Korea Cluster Headache Market
6.4.1 South Korea Cluster Headache Market by Distribution channel
6.4.2 South Korea Cluster Headache Market by Type
6.4.3 South Korea Cluster Headache Market by Drug Class
6.5 Singapore Cluster Headache Market
6.5.1 Singapore Cluster Headache Market by Distribution channel
6.5.2 Singapore Cluster Headache Market by Type
6.5.3 Singapore Cluster Headache Market by Drug Class
6.6 Malaysia Cluster Headache Market
6.6.1 Malaysia Cluster Headache Market by Distribution channel
6.6.2 Malaysia Cluster Headache Market by Type
6.6.3 Malaysia Cluster Headache Market by Drug Class
6.7 Rest of Asia Pacific Cluster Headache Market
6.7.1 Rest of Asia Pacific Cluster Headache Market by Distribution channel
6.7.2 Rest of Asia Pacific Cluster Headache Market by Type
6.7.3 Rest of Asia Pacific Cluster Headache Market by Drug Class
Chapter 7. Company Profiles
7.1 Dr. Reddy’s Laboratories Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expenses
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Pfizer, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional & Segmental Analysis
7.6.4 Research & Development Expense
7.7 Fresenius SE & Co. KGaA
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Grünenthal GmbH
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.10. Arrotex Pharmaceuticals Pty Limited
7.10.1 Company Overview
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Methodology
LOADING...
